Skip to content
MarketHOT
中文
← Latest news

6-K - NOVO NORDISK A S (0000353278) (Filer)

SEC · EDGAR 财务披露 · November 5, 2026 at 1:06 PM ET

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

November 5, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf ..

Please find below a statement of such trading in shares issued by Novo Nordisk.

Page 2 of 3

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Martin Holst Lange
2 Reason for the notification
a) Position/status Executive Vice President, R&D and Chief Scientific Officer (CSO)
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)

Description of the financial instrument,

type of instrument,

Shares    
Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares
c) Price(s) and volume(s)  
  Price(s) Volume(s)  
DKK 285.00 12,000
   
d)

Aggregated information

·        Aggregated volume

·        Price

12,000

DKK 3,420 ,000 .0 0

e) Date of the transaction 20 26-11-04
f) Place of the transaction Nasdaq Copenhagen
     
     

Page 3 of 3

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo -B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram , LinkedIn, TikTok, Facebook , X and YouTube.

Contacts for further information

Novo Media:  

Ambre James -Brown

+45 3079 9289

[email protected]

Liz Skrbkova (US)

+1 609 917 0632

[email protected]

   
Novo Investors:  

Michael Novod

+45 3075 6050

[email protected]

Sina Meyer

+45 3079 6656

[email protected]

   

Max Ung

+45 3077 6414

[email protected]

Christoffer Togo Solgaard -Tullin

+45 3079 1471

[email protected]

   

Ida Schaap Melvold

+45 3077 5649

[email protected]

Mads Berner Bruun

+45 3075 2936

[email protected]

   

Frederik Taylor Pitter (US)

+1 609 613 0568

[email protected]

Alex Bruce (US)

+1 640 230 0276

[email protected]

Novo Nordisk A/S

Investor Relations

Novo Allé 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

   Company announcement No 66 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 5, 2026

NOVO NORDISK A/S

Maziar Mike Doustdar

Chief Executive Officer

View source ↗ · 中文页面